Lifeward Ltd. LFWD 深 滬
等待開盤 01-29 09:30:00 美东时间
0.6558
-0.004
-0.64%
華盛通- 最 高0.69
- 今 開0.66
- 成交量 13.22万股
- 最 低 0.65
- 昨 收 0.66
- 總市值 1199.71万
- 52周最高 2.95
- 市盈率 靜 --
- 換手率 0.72%
- 52周最低 0.501
- 委 比 96.55%
- 總股本 1829.38万
- 歷史最高 7648.55
- 量 比 0.58
- 振 幅 6.06%
- 歷史最低 0.501
- 每 手 1
- 風險率 0.44%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Oramed Pharmaceuticals To Acquire 49.99% Stake In 49.99%, To Integrate Proprietary Protein Oral Delivery Technology; Lifeward To Issue $10M Convertible Notes, Oramed To Invest $9M Of Convertible Notes
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) ("Oramed") and Lifeward Ltd. (NASDAQ: LFWD) ("Lifeward") today announced the signing of binding agreements for a strategic transaction between Oramed, Lifeward and a
01-13 21:04
Oramed and Lifeward Announce Strategic Transaction
Transaction Will Transfer Oramed's Oral Drug Delivery Platform (POD™ Technology) to Lifeward and Positions Oramed as a Significant Shareholder Oramed will transfer POD™ platform to Lifeward ...
01-13 20:58
Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company
Lifeward Ltd has secured up to $47 million in strategic investment from Oramed Pharmaceuticals and another investor to drive profitability and diversify its portfolio into biotech. Lifeward acquired Oramed's Protein Oral Delivery (POD™) technology, targeting the $600+ billion injectable drugs market, including the potential first oral insulin medicine, ORMD-0801. The transaction allows Lifeward to focus on existing MedTech products like ReWalk an...
01-13 13:00
Lifeward Appoints Bob Marshall Board Chairman, Effective Jan. 1, Succeeding Joseph Turk
Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, announced today that its
2025-12-20 05:06
Lifeward Expands Patient Access To ReWalk Personal Exoskeleton Through New International Distribution Agreement With Verita Neuro
Distribution agreement with Singapore-based Verita Neuro will provide patients the ReWalk Personal Exoskeleton as part of its multi-layered treatment modalitiesNew delivery model for ReWalk will integrate in-patient
2025-12-17 21:13
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
2025-11-19 11:01
Lifeward Gets First Prior Authorization From UnitedHealthcare Medicare Advantage Plan For ReWalk 7 Personal Exoskeleton
Lifeward Ltd., (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, announced today that it received
2025-11-17 21:05
电话会总结 ｜ Lifeward(LFWD)2025财年Q3业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Lifeward业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 总营收620万美元，同比增长1.1%（去年同期610万美元），环比增长8%（上季度570万美元） - 传统产品营收310万美元，同比增长24%（去年同期250万美元），主要由ReWalk产品贡献290万美元 - ATLAS G产品营收310万美元，同比下降13.9%（去年同期360万美元） **盈利能力：** - GAAP毛利润270万美元，毛利率43.7%，同比提升7.5个百分点（去年同期220万美元，毛利率36.2%） - Non-GAAP毛利
2025-11-15 12:13
Lifeward Affirms FY2025 Sales Guidance of $24.000M-$26.000M vs $25.101M Est
Lifeward (NASDAQ:LFWD) affirms FY2025 sales outlook from $24.000 million-$26.000 million to $24.000 million-$26.000 million vs $25.101 million estimate.
2025-11-14 21:02
Lifeward Q3 Adj. EPS $(0.19) Beats $(0.21) Estimate, Sales $6.195M Miss $6.311M Estimate
Lifeward (NASDAQ:LFWD) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.21) by 11.63 percent. This is a 57.78 percent increase over losses of $(0.45) per share from the same
2025-11-14 21:01
